Phenylketonuria
Drug research and approvals for phenylketonuria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 31 studies of phenylketonuria are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 4 approved and 11 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 31
- Trials authorized in Canada: 6
- FDA orphan approvals: 4
- EU medicines: 4
- The Impact of Frequency of Home Phenylalanine Measurements on Metabolic Control in a Population of Patients With…NCT07825883 · Not applicable · Michał Kania · starts Sep 11, 2026
- Impact Of A Phe-Restricted Diet On Gut Health In Children With PKUNCT07728032 · Not reported · Birmingham Women's and Children's NHS Foundation Trust · starts Oct 1, 2025
- A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to…NCT07713758 · Phase 1 · Otsuka Pharmaceutical Development & Commercialization, Inc. · starts Jul 17, 2026
- Eating Disorders in Patients With PhenylketonuriaNCT07698743 · Not reported · Central Hospital, Nancy, France · starts Dec 4, 2025
- A Study of MZE782 in Adults With PKUNCT07694440 · Phase 2 · Maze Therapeutics · starts Jun 23, 2026
- GenSci144 Tablets Phase I Clinical TrialNCT07685210 · Phase 1 · Changchun GeneScience Pharmaceutical Co., Ltd. · starts Jun 22, 2026
- A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)NCT07672756 · Phase 1 · Chongqing Peg-Bio Biopharm Co., Ltd. · starts Jul 20, 2025
- PheCheck™ Validation StudyNCT07551921 · Not reported · Aptatek BioSciences, Inc · starts Aug 20, 2026
- Multiomics Approach in Adult Patients With PhenylketonuriaNCT07484945 · Not reported · University Hospital, Tours · starts Mar 23, 2026
How its trials ended
165 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 39 whose ending is known, 38% met their primary endpoint, 3% missed it and 59% stopped early.
- Completed, result not reported8149%
- Ongoing4024%
- Met its primary endpoint159%
- Stopped: other or unclear106%
- Stopped: enrollment or feasibility64%
- Stopped: sponsor or business decision53%
- Status unknown53%
- Missed its primary endpoint11%
- Stopped: lack of efficacy11%
- Stopped: funding11%
| Aug 27, 2026 | An open-label study to evaluate the long-term safety of JNT-517 in participants with phenylketonuriaRepinatrabit (JNT-517) | Otsuka Holdings | Pending |
| Sep 12, 2025 | A phase 3, double-blind, randomized, two-period, multicenter, placebo controlled, efficacy and safety study of JNT-517 for the treatment of participants with…Repinatrabit (JNT-517) | Otsuka Holdings | Ongoing |
| Nov 14, 2023 | A phase 3, randomized, crossover, open-label, active-controlled study of sepiapterin versus sapropterin in participants with phenylketonuria >2 years of ageSepiapterin | PTC Therapeutics | Closed |
| Apr 5, 2023 | A phase 3, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of SYNB1934 in patients with pku (synpheny-3)SYNB1934 / Esomeprazole / Ondansetron hydrochloride dihydrate | Synlogic Operating Company Inc. | Ongoing |
| Sep 29, 2021 | A phase 3 study of PTC923 in subjects with phenylketonuriaPTC923 | PTC Therapeutics | Closed |
| Sep 29, 2021 | A phase 3 open-label study of sepiapterin (PTC923) in phenylketonuriaSepiapterin (PTC923) | PTC Therapeutics | Closed |
| Feb 27, 2026 | PalynziqTo reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have… | BioMarin Pharmaceutical Inc. | Approved |
| Jul 28, 2025 | SephienceTreatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive… | PTC Therapeutics, Inc. | Approved |
| May 24, 2018 | PalynziqPalynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood… | BioMarin Pharmaceutical Inc. | Approved |
| Dec 13, 2007 | KuvanIndicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-)… | BioMarin Pharmaceutical, Inc. | Approved |
| Dec 13, 2025 | Recombinant adeno-associated virus serotype 8-based gene…Treatment of phenylketonuria | Gritgen Therapeutics Co., Ltd. | Designated |
| Oct 9, 2024 | An in vivo target-primed reverse transcription genome…Treatment of phenylketonuria | Tessera Therapeutics, Inc. | Designated |
| Apr 24, 2024 | (R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)…Treatment of phenylketonuria | Jnana Therapeutics | Designated |
| Dec 27, 2023 | Small molecule chaperone to stabilize and rescue the…Treatment of Phenylketonuria | Pluvia AS | Designated |
| Sep 8, 2023 | Adeno-associated virus (AAV)-based vector with an…Treatment of phenylketonuria (PKU) | Sanofi US Services, Inc. | Designated |
| May 8, 2023 | A phenylalanine consuming engineered bacteriaTreatment of Phenylketonuria (PKU) | Synlogic Operating Company, Inc. | Designated |
| Jan 9, 2023 | Recombinant adeno-associated virus serotype 8 vector…Treatment of Phenylketonuria (PKU) | Nggt Inc. | Designated |
| Mar 23, 2020 | L-serine, L-threonine, L-leucine, glycine, L-alanine,…Treatment of phenylketonuria | APR Applied Pharma Research | Designated |
| Oct 21, 2019 | Adeno-associated virus vector encoding human phenylalanine…Treatment of phenylketonuria | BioMarin Pharmaceutical, Inc. | Designated |
| Oct 15, 2018 | Recombinant lentivirus vector expressing the human…Treatment of Phenylketonuria | American Gene Technologies International Inc. | Designated |
| Oct 18, 2017 | A strain of modified live probiotic bacterium Escherichia…Treatment of phenylketonuria (PKU) | Synlogic, Inc. | Designated |
| Jun 19, 2025 | SephienceSepiapterin · orphan | PTC Therapeutics International Limited | EMA ↗ |
| Feb 16, 2022 | Sapropterin DipharmaSapropterin · generic | Dipharma Arzneimittel GmbH | EMA ↗ |
| May 3, 2019 | PalynziqPegvaliase · orphan | BioMarin International Limited | EMA ↗ |
| Dec 2, 2008 | KuvanSapropterin | BioMarin International Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA